Taiwan Glass Industry Corp.(TW:1802)
NT$76.70+6.90 (+9.89%)
TW:1802
Taiwan Glass Industry Corp. stock drug pipeline
NT$76.70
At close:+6.90 (+9.89%)
Taiwan Glass Industry Corp. (1802) Drug Pipeline
This company reports no clinical trials.
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Taiwan Glass Industry Corp. (TW:1802) have in its pipeline
Taiwan Glass Industry Corp. TW:1802 does not currently report any drugs in clinical development.
